Compare SNX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNX | INM |
|---|---|---|
| Founded | 1980 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 3.7M |
| IPO Year | 2003 | N/A |
| Metric | SNX | INM |
|---|---|---|
| Price | $152.68 | $1.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $168.60 | N/A |
| AVG Volume (30 Days) | ★ 779.5K | 159.3K |
| Earning Date | 01-08-2026 | 02-11-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 18.98 | N/A |
| EPS | ★ 9.21 | N/A |
| Revenue | ★ $60,973,509,000.00 | $4,798,116.00 |
| Revenue This Year | $7.25 | N/A |
| Revenue Next Year | $4.35 | N/A |
| P/E Ratio | $16.67 | ★ N/A |
| Revenue Growth | ★ 6.94 | N/A |
| 52 Week Low | $92.23 | $1.03 |
| 52 Week High | $167.76 | $8.27 |
| Indicator | SNX | INM |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 39.32 |
| Support Level | $149.96 | $1.03 |
| Resistance Level | $155.06 | $1.35 |
| Average True Range (ATR) | 3.05 | 0.10 |
| MACD | -0.16 | -0.00 |
| Stochastic Oscillator | 49.30 | 22.22 |
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.